吡非尼酮
粉防己碱
自噬
成纤维细胞
肺纤维化
纤维化
特发性肺纤维化
医学
组织重塑
药理学
癌症研究
化学
肺
免疫学
病理
体外
生物化学
内科学
炎症
细胞凋亡
作者
Xinrui Zhang,Xiangfeng Duan,Xiuzhi Xie,Dan Zhang,Yuan Chen,Ruibing Yu,Yujie Zhou,Yuteng Chu,Jie Shen,Yue Cai,Xuanrong Sun
标识
DOI:10.1002/adhm.202501916
摘要
Idiopathic pulmonary fibrosis (IPF), a lethal respiratory disease with few treatment options, occurs due to an excessive process of epithelial-mesenchymal transition (EMT) and abnormal accumulation of extracellular matrix (ECM), eventually leading to fibrotic scarring and destruction of alveolar structures. Here, a bioinspired inhalable nanocomplex (CCMφ@PTNPs) is reported for inhibiting the EMT progress and clearing the intrapulmonary ECM, thereby reversing established fibrotic foci in IPF. The nanocomplex consists of a PLGA core loaded with Chinese herbal tetrandrine (TET) and pirfenidone (PFD), and a macrophage cell membrane (Mφ) shell modified with collagenase type I (CLN) and collagen-targeting peptide (CBP). Following inhalation, CCMφ@PTNPs achieves precise abilities of targeting and degrading collagen barrier with the aid of CBP and CLN, ultimately achieving efficient penetration and drug delivery of fibrotic lesions in alveoli. The co-delivery of PFD and TET not only inhibited the transforming growth factor-β1(TGF-β1) pathway to achieve collagen modulation but also restored TGF-β1-induced impaired autophagy, which ultimately reduced local collagen production and accelerated clearance, thus synergistically enhancing the lung function of the bleomycin-induced mouse model. In summary, this study proposes a novel inhalation drug delivery strategy for the treatment of IPF.
科研通智能强力驱动
Strongly Powered by AbleSci AI